Table 1 Patient characteristics of the SEER-Oncotype cohort. P values were calculated by t-test and chi-squared test for continuous and categorical characteristics, respectively
From: Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use
| Users (n = 89,255) | Non-users (n = 286,095) | P value | |
|---|---|---|---|
| Mean age (SD) | 57.8 (10.0) | 59.5 (11.5) | <1e−314 |
| Stage (%) | <1e−314 | ||
| I | 58,512 (65.6) | 132,415 (46.3) | |
| II | 29,494 (33.0) | 97,347 (34.0) | |
| III | 1104 (1.2) | 40,265 (14.1) | |
| IV | 145 (0.2) | 16,068 (5.6) | |
| Grade (%) | <1e−314 | ||
| I | 70,648 (26.1) | 25,215 (28.9) | |
| II | 126,526 (46.8) | 47,690 (54.7) | |
| III | 73,256 (27.1) | 14,338 (16.4) | |
| Lymph node (%) | <1e−314 | ||
| Negative | 76,401 (85.6) | 174,024 (60.8) | |
| Positive | 12,848 (14.4) | 109,956 (38.4) | |
| Unknown | 6 (0.0) | 2115 (0.8) | |
| HER2 (%) a | <1e−314 | ||
| Negative | 62,115 (95.3) | 112,187 (78.2) | |
| Positive | 1199 (1.8) | 24,469 (17.1) | |
| Unknown | 1889 (2.9) | 6850 (4.7) | |
| Race (%) | 3.E−71 | ||
| White | 73,722 (82.6) | 230,090 (80.4) | |
| Black | 7129 (8.0) | 69,307 (10.0) | |
| Asian | 6837 (7.7) | 22,592 (7.9) | |
| Other | 1293 (1.4) | 3962 (1.4) | |
| Unknown | 274 (0.3) | 851 (0.3) | |
| Chemotherapy (%) | <1e−314 | ||
| No/unknown | 67,853 (77.7) | 159,334 (55.7) | |
| Yes | 19,948 (22.3) | 126,761 (44.3) | |
| Radiation therapy (%) | 7.E−313 | ||
| No/unknown | 34,763 (38.9) | 132,040 (46.2) | |
| Yes | 54,492 (61.1) | 154,055 (53.8) |